Literature DB >> 31135884

On models for the estimation of the excess mortality hazard in case of insufficiently stratified life tables.

Francisco J Rubio1, Bernard Rachet2, Roch Giorgi3, Camille Maringe4, Aurélien Belot4.   

Abstract

In cancer epidemiology using population-based data, regression models for the excess mortality hazard is a useful method to estimate cancer survival and to describe the association between prognosis factors and excess mortality. This method requires expected mortality rates from general population life tables: each cancer patient is assigned an expected (background) mortality rate obtained from the life tables, typically at least according to their age and sex, from the population they belong to. However, those life tables may be insufficiently stratified, as some characteristics such as deprivation, ethnicity, and comorbidities, are not available in the life tables for a number of countries. This may affect the background mortality rate allocated to each patient, and it has been shown that not including relevant information for assigning an expected mortality rate to each patient induces a bias in the estimation of the regression parameters of the excess hazard model. We propose two parametric corrections in excess hazard regression models, including a single-parameter or a random effect (frailty), to account for possible mismatches in the life table and thus misspecification of the background mortality rate. In an extensive simulation study, the good statistical performance of the proposed approach is demonstrated, and we illustrate their use on real population-based data of lung cancer patients. We present conditions and limitations of these methods and provide some recommendations for their use in practice.
© The Authors 2019. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  Excess mortality hazard; Exponentiated Weibull distribution; General hazard structure; Life tables; Net survival

Year:  2021        PMID: 31135884      PMCID: PMC7846106          DOI: 10.1093/biostatistics/kxz017

Source DB:  PubMed          Journal:  Biostatistics        ISSN: 1465-4644            Impact factor:   5.899


  6 in total

1.  A Flexible Bayesian Parametric Proportional Hazard Model: Simulation and Applications to Right-Censored Healthcare Data.

Authors:  Abdisalam Hassan Muse; Oscar Ngesa; Samuel Mwalili; Huda M Alshanbari; Abdal-Aziz H El-Bagoury
Journal:  J Healthc Eng       Date:  2022-06-02       Impact factor: 3.822

2.  Understanding disparities in cancer prognosis: An extension of mediation analysis to the relative survival framework.

Authors:  Elisavet Syriopoulou; Mark J Rutherford; Paul C Lambert
Journal:  Biom J       Date:  2020-12-14       Impact factor: 2.207

3.  Association between multimorbidity and socioeconomic deprivation on short-term mortality among patients with diffuse large B-cell or follicular lymphoma in England: a nationwide cohort study.

Authors:  Matthew James Smith; Edmund Njeru Njagi; Aurelien Belot; Clémence Leyrat; Audrey Bonaventure; Sara Benitez Majano; Bernard Rachet; Miguel Angel Luque Fernandez
Journal:  BMJ Open       Date:  2021-11-30       Impact factor: 2.692

4.  Direct modeling of the crude probability of cancer death and the number of life years lost due to cancer without the need of cause of death: a pseudo-observation approach in the relative survival setting.

Authors:  Dimitra-Kleio Kipourou; Maja Pohar Perme; Bernard Rachet; Aurelien Belot
Journal:  Biostatistics       Date:  2022-01-13       Impact factor: 5.899

5.  Marginal measures and causal effects using the relative survival framework.

Authors:  Elisavet Syriopoulou; Mark J Rutherford; Paul C Lambert
Journal:  Int J Epidemiol       Date:  2020-04-01       Impact factor: 7.196

6.  Correcting inaccurate background mortality in excess hazard models through breakpoints.

Authors:  Robert Darlin Mba; Juste Aristide Goungounga; Nathalie Grafféo; Roch Giorgi
Journal:  BMC Med Res Methodol       Date:  2020-10-29       Impact factor: 4.615

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.